Review anchor
RAC-alpha serine/threonine-protein kinase
SINGLE PROTEIN · Mus musculus
As of 2026-09-13
Evidence Snapshot
RAC-alpha serine/threonine-protein kinase
CHEMBL5859
SINGLE PROTEIN
Mus musculus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RAC-alpha serine/threonine-protein kinase as ChEMBL target CHEMBL5859, mapped to UniProt P31750. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5859
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P31750
RAC-alpha serine/threonine-protein kinase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why RAC-alpha serine/threonine-protein kinase matters
RAC-alpha serine/threonine-protein kinase is reviewed as RAC-alpha serine/threonine-protein kinase (UniProt P31750); the current evidence base includes 0 approved drugs, 110 compounds, and 79 assays, with lead potency reaching pChEMBL 7.7.
Protein context
RAC-alpha serine/threonine-protein kinase
RAC-alpha serine/threonine-protein kinase Sequence length is 480 aa.
Review this target as RAC-alpha serine/threonine-protein kinase, mapped to UniProt P31750. Sequence length is 480 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P31750
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 110 compounds, and 79 assays for this target. The dominant activity type is KI. CHEMBL575448 is the current potency anchor at pChEMBL 7.7.
Use CHEMBL575448 as the tractability anchor when discussing potency (pChEMBL 7.7).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 7.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why RAC-alpha serine/threonine-protein kinase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P31750, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
110
Total Compounds
79
Total Assays
0
Approved Drugs
IC50: 1.0, KI: 49.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL575448
|
7.7 | IC50 | Clinical |
|
|
No preferred name
CHEMBL1685065
|
6.3 | Ki | — |
|
|
No preferred name
CHEMBL1685066
|
5.8 | Ki | — |
|
|
No preferred name
CHEMBL595583
|
5.6 | Ki | — |
|
|
No preferred name
CHEMBL1685055
|
5.4 | Ki | — |
Source Header